The original SPF10 LiPA25 algorithm is more sensitive and suitable for epidemiologic HPV research than the SPF10 INNO-LiPA Extra

Journal of Virological Methods

Volumn 215-216, Issue , 2015, Pages 22-29

  Geraets, Daan T ^a   Struijk, Linda ^a   Kleter, Bernhard ^a   Molijn, Anco ^a   van Doorn, Leen Jan ^a   Quint, Wim G V ^a   Colau, Brigitte ^b  

^a DDL DIAGNOSTIC LABORATORY   (Netherlands)

^b GSK   (Belgium)

Author keywords

Epidemiology; Genotyping; Human papillomavirus; INNO LiPA; LiPA25; SPF10

Indexed keywords

VIRUS DNA;

ARTICLE; CONTROLLED STUDY; DNA PROBE; FEMALE; GENETIC ALGORITHM; GENOTYPING TECHNIQUE; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; MEDICAL RESEARCH; MOLECULAR DYNAMICS; NONHUMAN; PRIORITY JOURNAL; PROCESS DEVELOPMENT; SENSITIVITY ANALYSIS; SPF10 INNO LIPA25 ALGORITHM; SPF10 LIPA25 ALGORITHM; UTERINE CERVIX BIOPSY; VIRUS GENOME; VIRUS IDENTIFICATION; WART VIRUS; ALGORITHM; CLASSIFICATION; COMPARATIVE STUDY; EVALUATION STUDY; GENETICS; ISOLATION AND PURIFICATION; MOLECULAR DIAGNOSIS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PROCEDURES; REPRODUCTIVE TRACT INFECTIONS; SENSITIVITY AND SPECIFICITY; VIROLOGY;

HUMAN PAPILLOMAVIRUS;

ALGORITHMS; FEMALE; GENOTYPING TECHNIQUES; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; REPRODUCTIVE TRACT INFECTIONS; SENSITIVITY AND SPECIFICITY; VIROLOGY;

EID: 84923923774     PISSN: 01660934     EISSN: 18790984     Source Type: Journal    
DOI: 10.1016/j.jviromet.2015.01.001     Document Type: Article

References (33)

1. Alemany L., Saunier M., Alvarado-Cabrero I., Quiros B., Salmeron J., Shin H.R., Pirog E.C., Guimera N., Hernandez-Suarez G., Felix A., Clavero O., Lloveras B., Kasamatsu E., Goodman M.T., Hernandez B.Y., Laco J., Tinoco L., Geraets D.T., Lynch C.F., Mandys V., Poljak M., Jach R., Verge J., Clavel C., Ndiaye C., Klaustermeier J., Cubilla A., Castellsague X., Bravo I.G., Pawlita M., Quint W.G., Munoz N., Bosch F.X., de Sanjose S. Human papillomavirus DNA prevalence and type distribution in anal carcinomas worldwide. Int. J. Cancer 2014, 136:98-107.
2. Alemany L., Saunier M., Tinoco L., Quiros B., Alvarado-Cabrero I., Alejo M., Joura E.A., Maldonado P., Klaustermeier J., Salmeron J., Bergeron C., Petry K.U., Guimera N., Clavero O., Murillo R., Clavel C., Wain V., Geraets D.T., Jach R., Cross P., Carrilho C., Molina C., Shin H.R., Mandys V., Nowakowski A.M., Vidal A., Lombardi L., Kitchener H., Sica A.R., Magana-Leon C., Pawlita M., Quint W., Bravo I.G., Munoz N., de Sanjose S., Bosch F.X. Large contribution of human papillomavirus in vaginal neoplastic lesions: a worldwide study in 597 samples. Eur. J. Cancer 2014, 50:2846-2854.
3. Arbyn M., Ronco G., Anttila A., Meijer C.J., Poljak M., Ogilvie G., Koliopoulos G., Naucler P., Sankaranarayanan R., Peto J. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine 2012, 30(Suppl. 5):F88-F99.
4. Barzon L., Militello V., Pagni S., Palu G. Comparison of INNO-LiPA Genotyping Extra and Hybrid Capture 2 assays for detection of carcinogenic human papillomavirus genotypes. J. Clin. Virol. 2012, 55:256-261.
5. Castle P.E., Porras C., Quint W.G., Rodriguez A.C., Schiffman M., Gravitt P.E., Gonzalez P., Katki H.A., Silva S., Freer E., Van Doorn L.J., Jimenez S., Herrero R., Hildesheim A. Comparison of two PCR-based human papillomavirus genotyping methods. J. Clin. Microbiol. 2008, 46:3437-3445.
6. Colon-Lopez V., Quinones-Avila V., Del Toro-Mejias L.M., Reyes K., Rivera M.E., Nieves K., Sanchez-Vazquez M.M., Martinez-Ferrer M., Ortiz A.P. Oral HPV infection in a clinic-based sample of Hispanic men. BMC Oral Health 2014, 14:7.
7. Dartell M., Rasch V., Munk C., Kahesa C., Mwaiselage J., Iftner T., Kjaer S.K. Risk factors for high-risk human papillomavirus detection among HIV-negative and HIV-positive women from Tanzania. Sex. Transm. Dis. 2013, 40:737-743.
8. de Sanjose S., Quint W.G., Alemany L., Geraets D.T., Klaustermeier J.E., Lloveras B., Tous S., Felix A., Bravo L.E., Shin H.R., Vallejos C.S., de Ruiz P.A., Lima M.A., Guimera N., Clavero O., Alejo M., Llombart-Bosch A., Cheng-Yang C., Tatti S.A., Kasamatsu E., Iljazovic E., Odida M., Prado R., Seoud M., Grce M., Usubutun A., Jain A., Suarez G.A., Lombardi L.E., Banjo A., Menendez C., Domingo E.J., Velasco J., Nessa A., Chichareon S.C., Qiao Y.L., Lerma E., Garland S.M., Sasagawa T., Ferrera A., Hammouda D., Mariani L., Pelayo A., Steiner I., Oliva E., Meijer C.J., Al-Jassar W.F., Cruz E., Wright T.C., Puras A., Llave C.L., Tzardi M., Agorastos T., Garcia-Barriola V., Clavel C., Ordi J., Andujar M., Castellsague X., Sanchez G.I., Nowakowski A.M., Bornstein J., Munoz N., Bosch F.X. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010, 11:1048-1056.
9. de Sanjose S., Alemany L., Ordi J., Tous S., Alejo M., Bigby S.M., Joura E.A., Maldonado P., Laco J., Bravo I.G., Vidal A., Guimera N., Cross P., Wain G.V., Petry K.U., Mariani L., Bergeron C., Mandys V., Sica A.R., Felix A., Usubutun A., Seoud M., Hernandez-Suarez G., Nowakowski A.M., Wilson G., Dalstein V., Hampl M., Kasamatsu E.S., Lombardi L.E., Tinoco L., Alvarado-Cabrero I., Perrotta M., Bhatla N., Agorastos T., Lynch C.F., Goodman M.T., Shin H.R., Viarheichyk H., Jach R., Cruz M.O., Velasco J., Molina C., Bornstein J., Ferrera A., Domingo E.J., Chou C.Y., Banjo A.F., Castellsague X., Pawlita M., Lloveras B., Quint W.G., Munoz N., Bosch F.X. Worldwide human papillomavirus genotype attribution in over 2000 cases of intraepithelial and invasive lesions of the vulva. Eur. J. Cancer 2013, 49:3450-3461.
10. Einstein M.H., Baron M., Levin M.J., Chatterjee A., Fox B., Scholar S., Rosen J., Chakhtoura N., Meric D., Dessy F.J., Datta S.K., Descamps D., Dubin G. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: follow-up from months 12-24 in a Phase III randomized study of healthy women aged 18-45 years. Hum. Vaccines 2011, 7:1343-1358.
11. Galan-Sanchez F., Hernandez-Menendez M., De Los Rios Hernandez M.A., Rodriguez-Iglesias M. Performance of the New INNO-LiPA HPV Extra to genotype human papillomavirus in cervical cell specimens. Acta Cytol. 2011, 55:341-343.
12. Geraets D., Alemany L., Guimera N., de Sanjose S., de Koning M., Molijn A., Jenkins D., Bosch X., Quint W. Detection of rare and possibly carcinogenic human papillomavirus genotypes as single infections in invasive cervical cancer. J. Pathol. 2012, 228:534-543.
13. Geraets D.T., Grunberg A.W., van der Helm J.J., van der Loeff M.F.S., Quint K.D., Sabajo L.O., de Vries H.J. Cross-sectional study of genital carcinogenic HPV infections in Paramaribo, Suriname: prevalence and determinants in an ethnically diverse population of women in a pre-vaccination era. Sex. Transm. Infect 2014.
14. Herrero R., Wacholder S., Rodriguez A.C., Solomon D., Gonzalez P., Kreimer A.R., Porras C., Schussler J., Jimenez S., Sherman M.E., Quint W., Schiller J.T., Lowy D.R., Schiffman M., Hildesheim A. Prevention of persistent human papillomavirus infection by an HPV16/18 vaccine: a community-based randomized clinical trial in Guanacaste, Costa Rica. Cancer Discov. 2011, 1:408-419.
15. Hesselink A.T., van Ham M.A., Heideman D.A., Groothuismink Z.M., Rozendaal L., Berkhof J., van Kemenade F.J., Massuger L.A., Melchers W.J., Meijer C.J., Snijders P.J. Comparison of GP5+/6+-PCR and SPF10-line blot assays for detection of high-risk human papillomavirus in samples from women with normal cytology results who develop grade 3 cervical intraepithelial neoplasia. J. Clin. Microbiol. 2008, 46:3215-3221.
16. Hildesheim A., Wacholder S., Catteau G., Struyf F., Dubin G., Herrero R. Efficacy of the HPV-16/18 vaccine: final according to protocol results from the blinded phase of the randomized Costa Rica HPV-16/18 vaccine trial. Vaccine 2014, 32:5087-5097.
17. Kjaer S.K., Munk C., Junge J., Iftner T. Carcinogenic HPV prevalence and age-specific type distribution in 40,382 women with normal cervical cytology, ASCUS/LSIL, HSIL, or cervical cancer: what is the potential for prevention?. Cancer Causes Control 2014, 25:179-189.
18. Kleter B., van Doorn L.J., ter Schegget J., Schrauwen L., van Krimpen K., Burger M., ter Harmsel B., Quint W. Novel short-fragment PCR assay for highly sensitive broad-spectrum detection of anogenital human papillomaviruses. Am. J. Pathol. 1998, 153:1731-1739.
19. Kleter B., van Doorn L.J., Schrauwen L., Molijn A., Sastrowijoto S., ter Schegget J., Lindeman J., ter Harmsel B., Burger M., Quint W. Development and clinical evaluation of a highly sensitive PCR-reverse hybridization line probe assay for detection and identification of anogenital human papillomavirus. J. Clin. Microbiol. 1999, 37:2508-2517.
20. Kreimer A.R., Gonzalez P., Katki H.A., Porras C., Schiffman M., Rodriguez A.C., Solomon D., Jimenez S., Schiller J.T., Lowy D.R., van Doorn L.J., Struijk L., Quint W., Chen S., Wacholder S., Hildesheim A., Herrero R. Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial. Lancet Oncol. 2011, 12:862-870.
21. Lehtinen M., Paavonen J., Wheeler C.M., Jaisamrarn U., Garland S.M., Castellsague X., Skinner S.R., Apter D., Naud P., Salmeron J., Chow S.N., Kitchener H., Teixeira J.C., Hedrick J., Limson G., Szarewski A., Romanowski B., Aoki F.Y., Schwarz T.F., Poppe W.A., De Carvalho N.S., Germar M.J., Peters K., Mindel A., De Sutter P., Bosch F.X., David M.P., Descamps D., Struyf F., Dubin G. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 2012, 13:89-99.
22. Meijer C.J., Berkhof J., Castle P.E., Hesselink A.T., Franco E.L., Ronco G., Arbyn M., Bosch F.X., Cuzick J., Dillner J., Heideman D.A., Snijders P.J. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int. J. Cancer 2009, 124:516-520.
23. Mollers M., Scherpenisse M., van der Klis F.R., King A.J., van Rossum T.G., van Logchem E.M., Feltkamp M.C., Meijer C.J., Snijders P.J., Boot H.J., de Melker H.E. Prevalence of genital HPV infections and HPV serology in adolescent girls, prior to vaccination. Cancer Epidemiol. 2012, 36:519-524.
24. Munoz N., Bosch F.X., de Sanjose S., Herrero R., Castellsague X., Shah K.V., Snijders P.J., Meijer C.J. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N. Engl. J. Med. 2003, 348:518-527.
25. Schmeink C.E., Massuger L.F., Lenselink C.H., Quint W.G., Witte B.I., Berkhof J., Melchers W.J., Bekkers R.L. Prospective follow-up of 2,065 young unscreened women to study human papillomavirus incidence and clearance. Int. J. Cancer 2013, 133:172-181.
26. Snijders P.J., van den Brule A.J., Meijer C.J. The clinical relevance of human papillomavirus testing: relationship between analytical and clinical sensitivity. J. Pathol. 2003, 201:1-6.
27. Steinau M., Onyekwuluje J.M., Scarbrough M.Z., Unger E.R., Dillner J., Zhou T. Performance of commercial reverse line blot assays for human papillomavirus genotyping. J. Clin. Microbiol. 2012, 50:1539-1544.
28. Tjalma W.A., Fiander A., Reich O., Powell N., Nowakowski A.M., Kirschner B., Koiss R., O'Leary J., Joura E.A., Rosenlund M., Colau B., Schledermann D., Kukk K., Damaskou V., Repanti M., Vladareanu R., Kolomiets L., Savicheva A., Shipitsyna E., Ordi J., Molijn A., Quint W., Raillard A., Rosillon D., De Souza S.C., Jenkins D., Holl K. Differences in human papillomavirus type distribution in high-grade cervical intraepithelial neoplasia and invasive cervical cancer in Europe. Int. J. Cancer 2012, 132:854-867.
29. van Alewijk D., Kleter B., Vent M., Delroisse J.M., de Koning M., van Doorn L.J., Quint W., Colau B. A human papilloma virus testing algorithm comprising a combination of the L1 broad-spectrum SPF10 PCR assay and a novel E6 high-risk multiplex type-specific genotyping PCR assay. J. Clin. Microbiol. 2013, 51:1171-1178.
30. Van Damme P., Leroux-Roels G., Simon P., Foidart J.M., Donders G., Hoppenbrouwers K., Levin M., Tibaldi F., Poncelet S., Moris P., Dessy F., Giannini S.L., Descamps D., Dubin G. Effects of varying antigens and adjuvant systems on the immunogenicity and safety of investigational tetravalent human oncogenic papillomavirus vaccines: results from two randomized trials. Vaccine 2014, 32:3694-3705.
31. van Doorn L.J., Molijn A., Kleter B., Quint W., Colau B. Highly effective detection of human papillomavirus 16 and 18 DNA by a testing algorithm combining broad-spectrum and type-specific PCR. J. Clin. Microbiol. 2006, 44:3292-3298.
32. van Hamont D., van Ham M.A., Bakkers J.M., Massuger L.F., Melchers W.J. Evaluation of the SPF10-INNO LiPA human papillomavirus (HPV) genotyping test and the roche linear array HPV genotyping test. J. Clin. Microbiol. 2006, 44:3122-3129.
33. Wheeler C.M., Castellsague X., Garland S.M., Szarewski A., Paavonen J., Naud P., Salmeron J., Chow S.N., Apter D., Kitchener H., Teixeira J.C., Skinner S.R., Jaisamrarn U., Limson G., Romanowski B., Aoki F.Y., Schwarz T.F., Poppe W.A., Bosch F.X., Harper D.M., Huh W., Hardt K., Zahaf T., Descamps D., Struyf F., Dubin G., Lehtinen M. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 2012, 13:100-110.